Celcuity Inc

CELCNASDAQ · USD
64.37USD0.00 (+0.32%)
135

Celcuity Inc (CELC) Covered Calls

Celcuity Inc trades in the Biotechnology industry with an IV Rank of 71.23%, high versus the past year. CELC's highest covered call setup is the $80.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 24.28% out of the money with 7 days to expiration, a 24.36% return until expiration, and a 1,270.16% theoretical annualized return. Across the setups shown, annualized returns run from 154.63% to 1,270.16% at strikes between $65.00 and $185.00, with 7 to 434 days to expiration, as of Nov 13, 2026.

Read more

Running CELC covered calls helps you generate income from Celcuity Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CELC covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CELC stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CELC covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CELC covered call is worth writing.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer.

2026-11-20780.0024.280.052.151568.0024.361270.16-0.08+0.172392.10
2026-11-20770.008.750.201.75583.009.06472.26-0.31+0.242321.55
2027-01-156395.0047.580.052.803068.0047.66276.14-0.08+0.15392.75
2027-01-156390.0039.820.053.702568.0039.89231.13-0.08+0.192573.65
2027-01-156385.0032.050.604.902123.0032.98191.08-0.93+0.25254.30
2026-12-183575.0016.510.154.301078.0016.75174.65-0.23+0.28254.15
2027-03-19126100.0055.350.854.203648.0056.67164.17-1.32+0.20543.35
2026-11-20765.000.981.354.40198.003.08160.39-2.10+0.502633.05
2028-01-21434185.00187.400.105.0012073.00187.56157.74-0.16+0.1444.90
2027-01-156380.0024.281.555.501718.0026.69154.63-2.41+0.31873.95

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank71.23% High
  • Market cap (M$)3,162
  • 52 weeks high-57.38%
  • 52 weeks low20.23%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$150.85
    134.35% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-4.71
  • EPS growth next 5 years—

As of Nov 13, 2026